Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice

Antioxidants and Redox Signaling

Volumn 27, Issue 14, 2017, Pages 1048-1066

  Langley, Monica ^a   Ghosh, Anamitra ^a   Charli, Adhithiya ^a   Sarkar, Souvarish ^a   Ay, Muhammet ^a   Luo, Jie ^a   Zielonka, Jacek ^b   Brenza, Timothy ^c   Bennett, Brian ^d   Jin, Huajun ^a   Ghaisas, Shivani ^a   Schlichtmann, Benjamin ^c   Kim, Dongsuk ^a   Anantharam, Vellareddy ^a   Kanthasamy, Arthi ^a   Narasimhan, Balaji ^c   Kalyanaraman, Balaraman ^b   Kanthasamy, Anumantha G ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c Iowa State University of Science and Technology   (United States)

^d Marquette University   (United States)

Author keywords

apocynin; Mito apocynin; Mitochondria; neuroprotection; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ACONITATE HYDRATASE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMYLASE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOCYNIN; BETA ACTIN; CALCIUM; CREATININE; DOPAMINE; GLUCOSE; HOMOVANILLIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITO APOCYNIN C 11; MITOCHONDRIAL TRANSCRIPTION FACTOR A; NEUROPROTECTIVE AGENT; NITRIC OXIDE; PHOSPHORUS; POTASSIUM; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SODIUM; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ACETOPHENONE DERIVATIVE; CYBB PROTEIN, MOUSE; DNA BINDING PROTEIN; HIGH MOBILITY GROUP PROTEIN; TFAM PROTEIN, MOUSE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BIOAVAILABILITY; BRAIN MITOCHONDRION; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; COORDINATION; CORPUS STRIATUM; DEGENERATIVE DISEASE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; EVALUATION STUDY; EXPERIMENTAL PARKINSONISM; IN VITRO STUDY; LOCOMOTION; MICROGLIA; MITOCHONDRIAL RESPIRATION; MOTOR DYSFUNCTION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NITRATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ROTAROD TEST; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; UREA NITROGEN BLOOD LEVEL; ANIMAL; CELL CULTURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENE KNOCKOUT; GENETICS; HUMAN; METABOLISM; MITOCHONDRION; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; TRANSGENIC MOUSE;

ACETOPHENONES; ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; GENE KNOCKOUT TECHNIQUES; HIGH MOBILITY GROUP PROTEINS; HUMANS; MICE; MICE, TRANSGENIC; MITOCHONDRIA; NADPH OXIDASE 2; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 85019331880     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2016.6905     Document Type: Article

References (75)

1. Anantharam V, Kaul S, Song C, Kanthasamy A, and Kanthasamy AG. Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells. Neurotoxicology 28: 988-997, 2007.
2. Belin AC, Bjork BF, Westerlund M, Galter D, Sydow O, Lind C, Pernold K, Rosvall L, Hakansson A, Winblad B, Nissbrandt H, Graff C, and Olson L. Association study of two genetic variants in mitochondrial transcription factor A (TFAM) in Alzheimer's and Parkinson's disease. Neurosci Lett 420: 257-262, 2007.
3. Blesa J and Przedborski S. Parkinson's disease: Animal models and dopaminergic cell vulnerability. Front Neuroanat 8: 155, 2014.
4. Block ML and Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35: 1127-1132, 2007.
5. Boone L, Meyer D, Cusick P, Ennulat D, Bolliger AP, Everds N, Meador V, Elliott G, Honor D, Bounous D, and Jordan H. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Pathol 34: 182-188, 2005.
6. Bove J and Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience 211: 51-76, 2012.
7. Case AJ, Li S, Basu U, Tian J, and Zimmerman MC. Mitochondrial-localized NADPH oxidase 4 is a source of superoxide in angiotensin II-stimulated neurons. Am J Physiol Heart Circ Physiol 305: H19-H28, 2013.
8. Charli A, Jin H, Anantharam V, Kanthasamy A, and Kanthasamy AG. Alterations in mitochondrial dynamics induced by tebufenpyrad and pyridaben in a dopaminergic neuronal cell culture model. Neurotoxicology 53: 302-313, 2016.
9. Chen SH, Oyarzabal EA, and Hong JS. Critical role of the Mac1/NOX2 pathway in mediating reactive microgliosisgenerated chronic neuroinflammation and progressive neurodegeneration. Curr Opin Pharmacol 26: 54-60, 2016.
10. Cochemé HM, Logan A, Prime TA, Abakumova I, Quin C, McQuaker SJ, Patel JV, Fearnley IM, James AM, Porteous CM, Smith RAJ, Hartley RC, Partridge L, and Murphy MP. Using the mitochondria-targeted ratiometric mass spectrometry probe MitoB to measure H2O2 in living Drosophila. Nat Protoc 7: 946-958, 2012.
11. Cochemé HM, Quin C, McQuaker SJ, Cabreiro F, Logan A, Prime TA, Abakumova I, Patel JV, Fearnley IM, James AM, Porteous CM, Smith RAJ, Saeed S, Carré JE, Singer M, Gems D, Hartley RC, Partridge L, and Murphy MP. Measurement of H2O2 within living drosophila during aging using a ratiometric mass spectrometry probe targeted to the mitochondrial matrix. Cell Metab 13: 340-350, 2011.
12. Cristovao AC, Choi DH, Baltazar G, Beal MF, and Kim YS. The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. Antioxid Redox Signal 11: 2105-2118, 2009.
13. Cristovao AC, Guhathakurta S, Bok E, Je G, Yoo SD, Choi DH, and Kim YS. NADPH oxidase 1 mediates alpha-synucleinopathy in Parkinson's disease. J Neurosci 32: 14465-14477, 2012.
14. Dagda RK, Cherra SJ, 3rd, Kulich SM, Tandon A, Park D, and Chu CT. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J Biol Chem 284: 13843-13855, 2009.
15. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med 51: 1289-1301, 2011.
16. Dodson MW and Guo M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr Opin Neurobiol 17: 331-337, 2007.
17. Dohi K, Ohtaki H, Nakamachi T, Yofu S, Satoh K, Miyamoto K, Song D, Tsunawaki S, Shioda S, and Aruga T. Gp91phox (NOX2) in classically activated microglia exacerbates traumatic brain injury. J Neuroinflammation 7: 41, 2010.
18. Dranka BP, Gifford A, Ghosh A, Zielonka J, Joseph J, Kanthasamy AG, and Kalyanaraman B. Diapocynin prevents early Parkinson's disease symptoms in the leucinerich repeat kinase 2 (LRRK2R(1)(4)(4)(1)G) transgenic mouse. Neurosci Lett 549: 57-62, 2013.
19. Dranka BP, Gifford A, McAllister D, Zielonka J, Joseph J, O'Hara CL, Stucky CL, Kanthasamy AG, and Kalyanaraman B. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease. Neurosci Lett 583: 159-164, 2014.
20. Dranka BP, Zielonka J, Kanthasamy AG, and Kalyanaraman B. Alterations in bioenergetic function induced by Parkinson's disease mimetic compounds: Lack of correlation with superoxide generation. J Neurochem 122: 941-951, 2012.
21. Duty S and Jenner P. Animal models of Parkinson's disease: A source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164: 1357-1391, 2011.
22. Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, Thams S, Bergstrand A, Hansson FS, Trifunovic A, Hoffer B, Cullheim S, Mohammed AH, Olson L, and Larsson NG. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 104: 1325-1330, 2007.
23. Fecke W, Sled VD, Ohnishi T, and Weiss H. Disruption of the gene encoding the NADH-binding subunit of NADH: Ubiquinone oxidoreductase in Neurospora crassa. Formation of a partially assembled enzyme without FMN and the ironsulphur cluster N-3. Eur J Biochem 220: 551-558, 1994.
24. Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, De-Mong DE, Ellis JM, Hyde LA, Lin Y, Markgraf CG, Mei H, Miller M, Poulet FM, Scott JD, Smith MD, Yin Z, Zhou X, Parker EM, Kennedy ME, and Morrow JA. MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther 355: 397-409, 2015.
25. Fifel K and Cooper HM. Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease. Neurobiol Dis 71: 359-369, 2014.
26. Finel M, Majander AS, Tyynela J, De Jong AM, Albracht SP, and Wikstrom M. Isolation and characterisation of subcomplexes of the mitochondrial NADH:ubiquinone oxidoreductase (complex I). Eur J Biochem 226: 237-242, 1994.
27. Galter D, Pernold K, Yoshitake T, Lindqvist E, Hoffer B, Kehr J, Larsson NG, and Olson L. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease. Genes Brain Behav 9: 173-181, 2010.
28. Gao HM, Liu B, and Hong JS. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 23: 6181-6187, 2003.
29. Gatt AP, Jones EL, Francis PT, Ballard C, and Bateman JM. Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies. Neurosci Lett 557 Pt B: 177-180, 2013.
30. Gaweda-Walerych K, Safranow K, Maruszak A, Bialecka M, Klodowska-Duda G, Czyzewski K, Slawek J, Rudzinska M, Styczynska M, Opala G, Drozdzik M, Kurzawski M, Szczudlik A, Canter JA, Barcikowska M, and Zekanowski C. Mitochondrial transcription factor A variants and the risk of Parkinson's disease. Neurosci Lett 469: 24-29, 2010.
31. Ghosh A, Chandran K, Kalivendi SV, Joseph J, Antholine WE, Hillard CJ, Kanthasamy A, Kanthasamy A, and Kalyanaraman B. Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic Biol Med 49: 1674-1684, 2010.
32. Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP, Kalyanaraman B, and Kanthasamy AG. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease. J Neuroinflammation 9: 241, 2012.
33. Ghosh A, Langley MR, Harischandra DS, Neal ML, Jin H, Anantharam V, Joseph J, Brenza T, Narasimhan B, Kanthasamy A, Kalyanaraman B, and Kanthasamy AG. Mitoapocynin treatment protects against neuroinflammation and dopaminergic neurodegeneration in a preclinical animal model of Parkinson's disease. J Neuroimmune Pharmacol 11: 259-278, 2016.
34. Good CH, Hoffman AF, Hoffer BJ, Chefer VI, Shippenberg TS, Bäckman CM, Larsson N-G, Olson L, Gellhaar S, Galter D, and Lupica CR. Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease. FASEB J 25: 1333-1344, 2011.
35. Gordon R, Hogan CE, Neal ML, Anantharam V, Kanthasamy AG, and Kanthasamy A. A simple magnetic separation method for high-yield isolation of pure primary microglia. J Neurosci Methods 194: 287-296, 2011.
36. Haddy A and Smith G. Transition metal and organic radical components of carp liver tissue observed by electron paramagnetic resonance spectroscopy. Comp Biochem Physiol Part B Biochem Mol Biol 123: 407-415, 1999.
37. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, and Golenbock DT. The NALP3 inflammasome is involved in the innate immune response to amyloid-[beta]. Nat Immunol 9: 857-865, 2008.
38. Hanson GR, Gates KE, Noble CJ, Griffin M, Mitchell A, and Benson S. XSophe-Sophe-XeprView: A computer simulation suite (v.1.1.3) for the analysis of continuous wave EPR spectra. J Inorg Biochem 98: 903-916, 2004.
39. Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, and Kanthasamy AG. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes. Biochim Biophys Acta 1842: 1282-1294, 2014.
40. Kennedy MC, Antholine WE, and Beinert H. An EPR investigation of the products of the reaction of cytosolic and mitochondrial aconitases with nitric oxide. J Biol Chem 272: 20340-20347, 1997.
41. Le Poul E, Bolea C, Girard F, Poli S, Charvin D, Campo B, Bortoli J, Bessif A, Luo B, Koser AJ, Hodge LM, Smith KM, DiLella AG, Liverton N, Hess F, Browne SE, and Reynolds IJ. A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease. J Pharmacol Exp Ther 343: 167-177, 2012.
42. Levesque S, Wilson B, Gregoria V, Thorpe LB, Dallas S, Polikov VS, Hong JS, and Block ML. Reactive microgliosis: Extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity. Brain 133: 808-821, 2010.
43. Li X, Redus L, Chen C, Martinez PA, Strong R, Li S, and O'Connor JC. Cognitive dysfunction precedes the onset of motor symptoms in the MitoPark mouse model of Parkinson's disease. PLoS One 8: E71341, 2013.
44. Lin MK and Farrer MJ. Genetics and genomics of Parkinson's disease. Genome Med 6: 48, 2014.
45. Lull ME and Block ML. Microglial activation and chronic neurodegeneration. Neurotherapeutics 7: 354-365, 2010.
46. Mander P and Brown GC. Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: A dual-key mechanism of inflammatory neurodegeneration. J Neuroinflammation 2: 20, 2005.
47. Martinez TN and Greenamyre JT. Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid Redox Signal 16: 920-934, 2012.
48. Miyazaki T, Iwasawa M, Nakashima T, Mori S, Shigemoto K, Nakamura H, Katagiri H, Takayanagi H, and Tanaka S. Intracellular and extracellular ATP coordinately regulate the inverse correlation between osteoclast survival and bone resorption. J Biol Chem 287: 37808-37823, 2012.
49. Morrison HW and Filosa JA. A quantitative spatiotemporal analysis of microglia morphology during ischemic stroke and reperfusion. J Neuroinflammation 10: 4, 2013.
50. Nakamaru-Ogiso E, Matsuno-Yagi A, Yoshikawa S, Yagi T, and Ohnishi T. Iron-sulfur cluster N5 is coordinated by an HXXXCXXCXXXXXC motif in the NuoG subunit of Escherichia coli NADH:quinone oxidoreductase (complex I). J Biol Chem 283: 25979-25987, 2008.
51. Naoi M, Maruyama W, Shamoto-Nagai M, Yi H, Akao Y, and Tanaka M. Oxidative stress in mitochondria: Decision to survival and death of neurons in neurodegenerative disorders. Mol Neurobiol 31: 81-93, 2005.
52. Nayernia Z, Jaquet V, and Krause KH. New insights on NOX enzymes in the central nervous system. Antioxid Redox Signal 20: 2815-2837, 2014.
53. Panicker N, Saminathan H, Jin H, Neal M, Harischandra DS, Gordon R, Kanthasamy K, Lawana V, Sarkar S, Luo J, Anantharam V, Kanthasamy AG, and Kanthasamy A. Fyn kinase regulates microglial neuroinflammatory responses in cell culture and animal models of Parkinson's disease. J Neurosci 35: 10058-10077, 2015.
54. Picca A, Pesce V, Fracasso F, Joseph AM, Leeuwenburgh C, and Lezza AM. Aging and calorie restriction oppositely affect mitochondrial biogenesis through TFAM binding at both origins of mitochondrial DNA replication in rat liver. PLoS One 8: E74644, 2013.
55. Pissadaki EK and Bolam JP. The energy cost of action potential propagation in dopamine neurons: Clues to susceptibility in Parkinson's disease. Front Comput Neurosci 7: 13, 2013.
56. Qin L, Liu Y, Hong JS, and Crews FT. NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia 61: 855-868, 2013.
57. Rossmeisl M, Rim JS, Koza RA, and Kozak LP. Variation in type 2 diabetes-related traits in mouse strains susceptible to diet-induced obesity. Diabetes 52: 1958-1966, 2003.
58. Salerno JC and Leigh JS. Crystal field of atypical low-spin ferriheme complexes. J Am Chem Soc 106: 2156-2159, 1984.
59. Schnell MA, Hardy C, Hawley M, Propert KJ, and Wilson JM. Effect of blood collection technique in mice on clinical pathology parameters. Hum Gene Ther 13: 155-161, 2002.
60. Sharma N and Nehru B. Characterization of the lipopolysaccharide induced model of Parkinson's disease: Role of oxidative stress and neuroinflammation. Neurochem Int 87: 92-105, 2015.
61. Simonyi A, Serfozo P, Lehmidi TM, Cui J, Gu Z, Lubahn DB, Sun AY, and Sun GY. The neuroprotective effects of apocynin. Front Biosci (Elite Ed) 4: 2183-2193, 2012.
62. Sloan M, Alegre-Abarrategui J, and Wade-Martins R. Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models. Biochem Soc Trans 40: 1080-1085, 2012.
63. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, and Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 95: 6469-6473, 1998.
64. Subash S, Essa MM, Al-Adawi S, Memon MA, Manivasagam T, and Akbar M. Neuroprotective effects of berry fruits on neurodegenerative diseases. Neural Regen Res 9: 1557-1566, 2014.
65. Subramaniam SR and Chesselet M-F. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol 0: 17-32, 2013.
66. Tansey MG and Goldberg MS. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37: 510-518, 2010.
67. Ulatowski LM and Manor D. Vitamin E and neurodegeneration. Neurobiol Dis 84: 78-83, 2015.
68. Varçin M, Bentea E, Michotte Y, and Sarre S. Oxidative stress in genetic mouse models of Parkinson's Disease. Oxid Med Cell Longev 2012: 624925, 2012.
69. Wang J, Silva JP, Gustafsson CM, Rustin P, and Larsson NG. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc Natl Acad Sci USA 98: 4038-4043, 2001.
70. Wang Q, Qian L, Chen SH, Chu CH, Wilson B, Oyarzabal E, Ali S, Robinson B, Rao D, and Hong JS. Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models. Brain 138: 1247-1262, 2015.
71. Xu Q, Shenoy S, and Li C. Mouse models for LRRK2 Parkinson's disease. Parkinsonism Relat Disord 18 Suppl 1: S186-S189, 2012.
72. Yakovlev G, Reda T, and Hirst J. Reevaluating the relationship between EPR spectra and enzyme structure for the iron sulfur clusters in NADH:quinone oxidoreductase. Proc Natl Acad Sci USA 104: 12720-12725, 2007.
73. Zielonka J, Cheng G, Zielonka M, Ganesh T, Sun A, Joseph J, Michalski R, O'Brien WJ, Lambeth JD, and Kalyanaraman B. High-throughput assays for superoxide and hydrogen peroxide: Design of a screening workflow to identify inhibitors of NADPH oxidases. J Biol Chem 289: 16176-16189, 2014.
74. Zielonka J, Sikora A, Adamus J, and Kalyanaraman B. Detection and differentiation between peroxynitrite and hydroperoxides using mitochondria-targeted arylboronic acid. Methods Mol Biol 1264: 171-181, 2015.
75. Zielonka J, Zielonka M, VerPlank L, Cheng G, Hardy M, Ouari O, Ayhan MM, Podsiadly R, Sikora A, Lambeth JD, and Kalyanaraman B. Mitigation of NADPH oxidase 2 activity as a strategy to inhibit peroxynitrite formation. J Biol Chem 291: 7029-7044, 2016.